March 2026 in “Frontiers in Bioscience-Elite” Duloxetine, escitalopram, and finasteride may be effective against bacteria and fungi.
6 citations
,
February 2020 in “Journal of Natural Products” A new compound from a sponge strongly inhibits an enzyme linked to male-pattern hair loss without being toxic at low levels.
6 citations
,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib helps regrow scalp, eyebrow, and eyelash hair in teens with severe alopecia areata.
2 citations
,
July 2007 in “Cancer biology & therapy” Bexxar is highly effective as a first treatment for non-Hodgkin's lymphoma, with most patients alive and many in remission after eight years.
January 2011 in “Reactions Weekly”
1 citations
,
July 2022 in “British Journal of Dermatology” Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.
16 citations
,
February 2009 in “Clinical neurology and neurosurgery” Switching to extended-release divalproex sodium improved patient-reported tremor but did not change seizure frequency or most side effects.
August 2008 in “European Neuropsychopharmacology” January 2004 in “Headache” Divalproex sodium significantly improved headaches in two-thirds of patients.
Baricitinib helped treat a man's beard hair loss when steroids didn't work.
42 citations
,
August 2012 in “Psychoneuroendocrinology” Finasteride reduces certain behaviors caused by D1-like receptor agonists but not by D2-like receptor agonists in mice.
January 2024 in “Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica/Revista de la Asociacion Colombiana de Dermatologia y Cirugia Dermatologica” Baricitinib successfully treated severe hair loss.
November 2023 in “JEADV Clinical Practice” Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Baricitinib significantly improves hair regrowth in severe alopecia areata.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly” 12 citations
,
August 2006 in “American Journal of Psychiatry” Topiramate may help improve disruptive behaviors in children with bipolar disorder.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib maintains significant hair regrowth in severe alopecia areata over three years.
October 2024 in “Clinical Cosmetic and Investigational Dermatology” Brevilin-A is a safe and effective treatment for mild to moderate alopecia areata in children.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in teens with severe alopecia areata.
9 citations
,
November 2004 in “Bioorganic & Medicinal Chemistry Letters” New compounds were made that effectively block enzymes related to prostate issues and hair loss.
156 citations
,
August 2014 in “Cochrane library” Budesonide is not effective for maintaining remission in Crohn's disease beyond three months.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
January 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in severe alopecia areata patients.
May 2024 in “Reactions weekly”
11 citations
,
February 2007 in “Journal of Child and Adolescent Psychiatric Nursing” Combining mood stabilizers with antipsychotics is more effective for treating children with bipolar disorder than using mood stabilizers alone.
13 citations
,
October 2010 in “Seizure” Extended-release valproate effectively reduced seizures and improved quality of life in epilepsy patients over 6 months, with some side effects.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Baricitinib is widely used for several conditions, especially COVID-19, but its safety and effectiveness are still being evaluated.